Patents by Inventor Fabian CHEN

Fabian CHEN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PHARMACEUTICAL USE
    Publication number: 20220133694
    Abstract: The present invention relates to novel methods and pharmaceutical compositions for the treatment of heart failure in a patient.
    Type: Application
    Filed: July 9, 2021
    Publication date: May 5, 2022
    Inventors: Adel Remond RIZKALA, Victor Chengwei SHI, Fabian CHEN
  • Sacubitril-valsartan dosage regimen for treating heart failure
    Patent number: 11058667
    Abstract: The present invention relates to sacubitril-valsartan dosage regimens for the treatment of heart failure in a patient.
    Type: Grant
    Filed: May 9, 2016
    Date of Patent: July 13, 2021
    Assignee: Novartis AG
    Inventors: Adel Remond Rizkala, Victor Chengwei Shi, Fabian Chen
  • Galenic formulations of organic compounds
    Patent number: 10722471
    Abstract: The present invention relates to a solid unit oral dosage form comprising sacubitril and valsartan in a 1:1 molar ratio, preferably in the form of the so-called angiotensin receptor neprilysin inhibitor (ARNI) LCZ696, which is a complex salt hydrate of sacubitril, valsartan, and sodium ions, appropriate for use in pediatrics or other patients where low and individual dosing is required or who encounter problems with swallowing e.g. as a result of a disease or because of age, to the manufacture of said solid dosage form and to invention embodiments relating to therapy using said dosage form.
    Type: Grant
    Filed: February 2, 2017
    Date of Patent: July 28, 2020
    Assignee: Novartis AG
    Inventors: Gesine Winzenburg, Bernd Trueby, Fabian Chen, Surya Prakash Ayalasomayajula, Christopher Bush, Masha Berkhin
  • GALENIC FORMULATIONS OF ORGANIC COMPOUNDS
    Publication number: 20190083406
    Abstract: The present invention relates to a solid unit oral dosage form comprising sacubitril and valsartan in a 1:1 molar ratio, preferably in the form of the so-called angiotensin receptor neprilysin inhibitor (ARNI) LCZ696, which is a complex salt hydrate of sacubitril, valsartan, and sodium ions, appropriate for use in pediatrics or other patients where low and individual dosing is required or who encounter problems with swallowing e.g. as a result of a disease or because of age, to the manufacture of said solid dosage form and to invention embodiments relating to therapy using said dosage form.
    Type: Application
    Filed: February 2, 2017
    Publication date: March 21, 2019
    Inventors: Gesine Winzenburg, Bernd Trueby, Fabian Chen, Surya Prakash Ayalasomayajula, Christopher Bush, Masha Berkhin
  • NEW USE OF A COMBINATION OF SACUBITRIL AND VALSARTAN
    Publication number: 20190054069
    Abstract: The present invention relates to methods and pharmaceutical compositions for treating heart failure in a pediatric human patient comprising administration to said patient of a therapeutically effective amount or a prophylactically effective amount of a combination of a therapeutic agent blocking the angiotensin receptor and a therapeutic agent inhibiting the NEP enzyme, in particular of a combination of sacubitril and valsartan in a pharmaceutically acceptable form and in a 1:1 molar ratio.
    Type: Application
    Filed: February 2, 2017
    Publication date: February 21, 2019
    Inventors: Fabian Chen, Surya Prakash Ayalasomayajula, Christopher Bush, Masha Berkhin, Gesine Winzenburg, Bernd Trueby
  • SACUBITRIL-VALSARTAN DOSAGE REGIMEN FOR TREATING HEART FAILURE
    Publication number: 20180125820
    Abstract: The present invention relates to sacubitril-valsartan dosage regimens for the treatment of heart failure in a patient.
    Type: Application
    Filed: May 9, 2016
    Publication date: May 10, 2018
    Inventors: Adel Remond Rizkala, Victor Chengwei SHI, Fabian CHEN